Prevention of HIV/AIDS – Historic Unitaid agreement to make lenacapavir accessible to low-income countries (September 25, 2025)

France welcomes the partnership agreement signed on September 24 between Unitaid, an organization co-founded and majority-funded by France, and Dr. Reddy’s Laboratories, the Clinton Health Access Initiative (CHAI) and Wits RHI.

This agreement will make it possible to produce and distribute a generic form of lenacapavir in 120 low- and middle-income countries for just $40 per person per year as soon as 2027. This treatment prevents HIV/AIDS infections with unprecedented effectiveness – nearly 100%.

The agreement comes a few weeks after the Global Fund to Fight AIDS, Tuberculosis and Malaria signed an agreement with Gilead, the laboratory that developed lenacapavir, to distribute enough doses at reduced prices to treat two million people in low- and middle-income countries.

France welcomes these major advances in the fight against HIV/AIDS and will remain fully committed to global health.